LALPATHLAB — Dr. Lal PathLabs Share Price
- IN₹227.36bn
- IN₹218.07bn
- IN₹22.27bn
- 100
- 8
- 91
- 78
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 45.35 | ||
PEG Ratio (f) | 3.34 | ||
EPS Growth (f) | 15.72% | ||
Dividend Yield (f) | 0.9% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 11.36 | ||
Price to Tang. Book | 19.36 | ||
Price to Free Cashflow | 46.29 | ||
Price to Sales | 9.46 | ||
EV to EBITDA | 32.49 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 24.78% | ||
Return on Equity | 22.09% | ||
Operating Margin | 22% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 13,303.57 | 15,812.66 | 20,874.08 | 20,168.82 | 22,266.41 | 24,693.29 | 27,635.77 | 13.1% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +13.32 | +28.89 | +18.06 | -31.13 | +49.98 | +20.86 | +15.72 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services in India. The Company offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its tests include Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, CBC Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Liver Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and Vitamin D Test. The Company has approximately 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore and Mumbai), 5,762 patient service centers (PSCs) and 11,619 pick-up points (PUPs). Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
Directors
- Arvind Lal CHM
- Bharath Uppiliappan CEO
- Ved Goel CFO
- Rajat Kalra CCO (43)
- Om Manchanda MDR (56)
- Vandana Lal EDR (63)
- Sunil Varma LED (78)
- Archana Erdmann NED
- Rahul Sharma NED (57)
- Harneet Chandhoke NID (55)
- Somya Satsangi NID
- Anoop Singh NID
- Saurabh Srivastava NID (75)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 14th, 1995
- Public Since
- December 23rd, 2015
- No. of Shareholders
- 150,768
- No. of Employees
- 4,099
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
National Stock Exchange of India
- Shares in Issue
- 83,367,273

- Address
- 12th Floor, GURGAON, 122001
- Web
- https://www.lalpathlabs.com/
- Phone
- +91 1243016500
- Contact
- Vinay Gujral
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for LALPATHLAB
Dr. Lal PathLabs Ltd Annual Shareholders Meeting
Q1 2026 Dr. Lal PathLabs Ltd Earnings Release
Similar to LALPATHLAB
Aatmaj Healthcare
National Stock Exchange of India
Apollo Hospitals Enterprise
National Stock Exchange of India
Artemis Medicare Services
National Stock Exchange of India
Aster DM Healthcare
National Stock Exchange of India
Chandan Healthcare
National Stock Exchange of India
FAQ
As of Today at 20:19 UTC, shares in Dr. Lal PathLabs are trading at IN₹2,727.20. This share price information is delayed by 15 minutes.
Shares in Dr. Lal PathLabs last closed at IN₹2,727.20 and the price had moved by +23.45% over the past 365 days. In terms of relative price strength the Dr. Lal PathLabs share price has outperformed the S&P BSE 100 Index by +14.37% over the past year.
The overall consensus recommendation for Dr. Lal PathLabs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Dr. Lal PathLabs dividend yield is 0.88% based on the trailing twelve month period.
Last year, Dr. Lal PathLabs paid a total dividend of IN₹24.00, and it currently has a trailing dividend yield of 0.88%. We do not have any data on when Dr. Lal PathLabs is to next pay dividends.
We do not have data on when Dr. Lal PathLabs is to next pay dividends. The historic dividend yield on Dr. Lal PathLabs shares is currently 0.88%.
To buy shares in Dr. Lal PathLabs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹2,727.20, shares in Dr. Lal PathLabs had a market capitalisation of IN₹227.36bn.
Here are the trading details for Dr. Lal PathLabs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: LALPATHLAB
Based on an overall assessment of its quality, value and momentum Dr. Lal PathLabs is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Dr. Lal PathLabs is IN₹3,107.24. That is 13.94% above the last closing price of IN₹2,727.20.
Analysts covering Dr. Lal PathLabs currently have a consensus Earnings Per Share (EPS) forecast of IN₹51.97 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dr. Lal PathLabs. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -14.49%.
As of the last closing price of IN₹2,727.20, shares in Dr. Lal PathLabs were trading -8.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dr. Lal PathLabs PE ratio based on its reported earnings over the past 12 months is 45.35. The shares last closed at IN₹2,727.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dr. Lal PathLabs' management team is headed by:
- Arvind Lal - CHM
- Bharath Uppiliappan - CEO
- Ved Goel - CFO
- Rajat Kalra - CCO
- Om Manchanda - MDR
- Vandana Lal - EDR
- Sunil Varma - LED
- Archana Erdmann - NED
- Rahul Sharma - NED
- Harneet Chandhoke - NID
- Somya Satsangi - NID
- Anoop Singh - NID
- Saurabh Srivastava - NID